Skip to content

DAILYZ HEALTH NEWS

ALL ABOUT DAILYZ HEALTH NEWS

  • Home
  • Infectious Disease
  • Metabolic
  • Neurological
  • Nutrition
  • Public Health

DAILYZ HEALTH NEWS

ALL ABOUT DAILYZ HEALTH NEWS

  • Home
  • Infectious Disease
  • Metabolic
  • Neurological
  • Nutrition
  • Public Health
Lp(a) reduction, neutral outcome
Health

Lp(a) HORIZON Trial: Lp(a) Fell by 78%, but Cardiovascular Outcomes Unexpectedly Neutral

November 8, 2026 Evan Vega

Lp(a) reduced 78% with pelacarsen, but cardiovascular outcomes showed no benefit in HORIZON trial.

Infant bleeding episodes jump
Health

U.S. Infant Bleeding Episodes Jump as Vitamin K Refusals Rise, Two Studies Find

November 8, 2026 Evan Vega
Amivantamab approved for HNSCC
Health

FDA Grants Accelerated Approval to Amivantamab and Hyaluronidase for Previously Treated HNSCC

November 7, 2026 Evan Vega
FDA approves Rybrevant Faspro
Health

FDA Approves Rybrevant Faspro for Advanced Head and Neck Cancer

November 7, 2026 Evan Vega
FDA Approves Pirtobrutinib Treatment
Health

FDA Approves Pirtobrutinib for Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

October 4, 2026 Evan Vega
Lp(a) reduction, neutral outcome
Health

Lp(a) HORIZON Trial: Lp(a) Fell by 78%, but Cardiovascular Outcomes Unexpectedly Neutral

November 8, 2026 Evan Vega

Lp(a) reduced 78% with pelacarsen, but cardiovascular outcomes showed no benefit in HORIZON trial.

Infant bleeding episodes jump
Health

U.S. Infant Bleeding Episodes Jump as Vitamin K Refusals Rise, Two Studies Find

November 8, 2026 Evan Vega
Amivantamab approved for HNSCC
Health

FDA Grants Accelerated Approval to Amivantamab and Hyaluronidase for Previously Treated HNSCC

November 7, 2026 Evan Vega
FDA approves Rybrevant Faspro
Health

FDA Approves Rybrevant Faspro for Advanced Head and Neck Cancer

November 7, 2026 Evan Vega
Lp(a) reduction, neutral outcome
Health

Lp(a) HORIZON Trial: Lp(a) Fell by 78%, but Cardiovascular Outcomes Unexpectedly Neutral

November 8, 2026 Evan Vega

Lp(a) reduced 78% with pelacarsen, but cardiovascular outcomes showed no benefit in HORIZON trial.

Infant bleeding episodes jump
Health

U.S. Infant Bleeding Episodes Jump as Vitamin K Refusals Rise, Two Studies Find

November 8, 2026 Evan Vega
Amivantamab approved for HNSCC
Health

FDA Grants Accelerated Approval to Amivantamab and Hyaluronidase for Previously Treated HNSCC

November 7, 2026 Evan Vega
FDA approves Rybrevant Faspro
Health

FDA Approves Rybrevant Faspro for Advanced Head and Neck Cancer

November 7, 2026 Evan Vega
FDA Approves Pirtobrutinib Treatment
Health

FDA Approves Pirtobrutinib for Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

October 4, 2026 Evan Vega
Lp(a) reduction, neutral outcome
Health

Lp(a) HORIZON Trial: Lp(a) Fell by 78%, but Cardiovascular Outcomes Unexpectedly Neutral

November 8, 2026 Evan Vega

Lp(a) reduced 78% with pelacarsen, but cardiovascular outcomes showed no benefit in HORIZON trial.

Infant bleeding episodes jump
Health

U.S. Infant Bleeding Episodes Jump as Vitamin K Refusals Rise, Two Studies Find

November 8, 2026 Evan Vega
Amivantamab approved for HNSCC
Health

FDA Grants Accelerated Approval to Amivantamab and Hyaluronidase for Previously Treated HNSCC

November 7, 2026 Evan Vega
FDA approves Rybrevant Faspro
Health

FDA Approves Rybrevant Faspro for Advanced Head and Neck Cancer

November 7, 2026 Evan Vega
Lp(a) reduction, neutral outcome
Health

Lp(a) HORIZON Trial: Lp(a) Fell by 78%, but Cardiovascular Outcomes Unexpectedly Neutral

November 8, 2026 Evan Vega

Lp(a) reduced 78% with pelacarsen, but cardiovascular outcomes showed no benefit in HORIZON trial.

Infant bleeding episodes jump
Health

U.S. Infant Bleeding Episodes Jump as Vitamin K Refusals Rise, Two Studies Find

November 8, 2026 Evan Vega
Amivantamab approved for HNSCC
Health

FDA Grants Accelerated Approval to Amivantamab and Hyaluronidase for Previously Treated HNSCC

November 7, 2026 Evan Vega
FDA approves Rybrevant Faspro
Health

FDA Approves Rybrevant Faspro for Advanced Head and Neck Cancer

November 7, 2026 Evan Vega
FDA Approves Pirtobrutinib Treatment
Health

FDA Approves Pirtobrutinib for Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

October 4, 2026 Evan Vega
Lp(a) reduction, neutral outcome
Health
November 8, 2026 Evan Vega

Lp(a) HORIZON Trial: Lp(a) Fell by 78%, but Cardiovascular Outcomes Unexpectedly Neutral

Lp(a) reduced 78% with pelacarsen, but cardiovascular outcomes showed no benefit in HORIZON trial.

Read More
Infant bleeding episodes jump
Health
November 8, 2026 Evan Vega

U.S. Infant Bleeding Episodes Jump as Vitamin K Refusals Rise, Two Studies Find

U.S. infant bleeding episodes rise as vitamin K shot refusals grow; rate fell from 97.7% to 95% (2017-2025) amid declining trust.

Read More
Amivantamab approved for HNSCC
Health
November 7, 2026 Evan Vega

FDA Grants Accelerated Approval to Amivantamab and Hyaluronidase for Previously Treated HNSCC

FDA grants accelerated approval to amivantamab/hyaluronidase for recurrent/metastatic HNSCC after platinum and PD-1/PD-L1 therapy, based on 42% ORR.

Read More
FDA approves Rybrevant Faspro
Health
November 7, 2026 Evan Vega

FDA Approves Rybrevant Faspro for Advanced Head and Neck Cancer

FDA grants accelerated approval to Rybrevant Faspro for adults with recurrent or metastatic head and neck squamous cell carcinoma.

Read More
FDA Approves Pirtobrutinib Treatment
Health
October 4, 2026 Evan Vega

FDA Approves Pirtobrutinib for Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia and small lymphocytic lymphoma without 17p deletion.

Read More
HHS Expands Mental Health
Health
October 4, 2026 Evan Vega

HHS Awards Nearly $250 Million to Expand Mental Health and Addiction Treatment Services

The U.S. HHS awarded $247.9 million in grants to expand mental health and addiction treatment services nationwide.

Read More
Ebola Worker Evacuated Congo
Health
October 3, 2026 Evan Vega

Doctors Without Borders Worker Evacuated After Contracting Ebola in Democratic Republic of Congo Outbreak

A Doctors Without Borders worker infected with Bundibugyo virus during DRC Ebola outbreak was evacuated to the Netherlands for specialized treatment.

Read More
FDA authorizes screwworm drugs
Health
September 16, 2026 Evan Vega

FDA issues emergency use authorization for drugs to prevent and treat New World screwworm in dogs and cats

The FDA authorized emergency use of Capstar and generic Nitenpyram to prevent and treat New World screwworm in dogs and cats nationwide.

Read More
FDA approves Alexander disease drug
Health
September 13, 2026 Evan Vega

FDA approves first drug to treat Alexander disease, offering a targeted therapy for the ultra-rare, progressive neurodegenerative disorder in children

The FDA approved Zanvastro, the first drug to treat Alexander disease by targeting abnormal GFAP buildup in pediatric and adult patients.

Read More
Listeria outbreak linked cheese
Health
September 13, 2026 Evan Vega

CDC and state health officials investigate multistate Listeria outbreak linked to soft-ripened cheese sold at Whole Foods Market, prompting nationwide recall and public warning to high-risk consumers

CDC and state officials investigated a 2013 multistate Listeria outbreak linked to Crave Brothers soft-ripened cheeses sold at Whole Foods, leading to a recall.

Read More
  • ← Previous
Copyright © 2026 DAILYZ HEALTH NEWS. Powered by ColorMag and WordPress.